Trial Profile
Afatinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring active EGFR mutations : an open-label, randomized, multicenter, phase II study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AfaBev-CS
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2019 Status changed from recruiting to discontinued.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.